Approved April 1998
TAP Holdings received approval from the U.S. Food and Drug Administration (FDA) for PREVACID(R) (lansoprazole) Delayed-Release Capsules in the short-term treatment of Symptomatic GERD. The most common symptom of GERD is heartburn caused by the reflux of gastric juices from the stomach into the esophagus.
PREVACID is well tolerated. The most frequently reported adverse events included headache, abdominal pain and diarrhea.
The PREVACID(R) (lansopraxole) drug information shown above is licensed from Thomson CenterWatch. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.